Raymond James analyst John Ransom raised the firm’s price target on Tenet Healthcare (THC) to $250 from $200 and keeps an Outperform rating on the shares. The firm said Q3 results exceeded expectations, as the company reported above-Street adjusted EBITDA. The quarter did benefit from a $38M out of period direct payment program, so the core beat was closer to roughly $23M all attributable to the hospital division, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $260 from $238 at UBS
- Tenet Healthcare price target raised to $232 from $225 at Morgan Stanley
- Tenet Healthcare price target raised to $238 from $221 at Guggenheim
- Tenet Healthcare Reports Strong Q3 2025 Results
- Strong Performance and Strategic Growth Drive Buy Rating for Tenet Healthcare